PD-L1 overexpression

News alerts, weekly reports and conference planners

Entrez ID:

29126

Related biomarkers:

‹

›

Related tests:

PD-L1 IHC 22C3 pharmDx (53)

VENTANA PD-L1 (SP263) Assay (31)

PD-L1 IHC 22C3 pharmDx (53)

VENTANA PD-L1 (SP263) Assay (31)

PD-L1 overexpression	Melanoma	PD-L1 overexpression	Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials Clin Cancer Res - 3 weeks (New B) nivolumab + ipilimumab Sensitive : B Clin Cancer Res - 3wk	nivolumab + ipilimumab Sensitive: B - Late Trials Clin Cancer Res - 3 weeks nivolumab + ipilimumab Sensitive : B Clin Cancer Res - 3 weeks - (New B)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2	cemiplimab-rwlc Sensitive: A2 - Guideline cemiplimab-rwlc Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials carboplatin + albumin-bound paclitaxel Sensitive : B	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials carboplatin + albumin-bound paclitaxel Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	carboplatin + gemcitabine Sensitive: B - Late Trials carboplatin + gemcitabine Sensitive : B	carboplatin + gemcitabine Sensitive: B - Late Trials carboplatin + gemcitabine Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials cisplatin + albumin-bound paclitaxel Sensitive : B	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials cisplatin + albumin-bound paclitaxel Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	GC Sensitive: B - Late Trials GC Sensitive : B	GC Sensitive: B - Late Trials GC Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	carboplatin + pemetrexed Sensitive: B - Late Trials carboplatin + pemetrexed Sensitive : B	carboplatin + pemetrexed Sensitive: B - Late Trials carboplatin + pemetrexed Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: B - Late Trials cisplatin + pemetrexed Sensitive : B	cisplatin + pemetrexed Sensitive: B - Late Trials cisplatin + pemetrexed Sensitive : B
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B	PD1 inhibitor Sensitive: B - Late Trials PD1 inhibitor Sensitive : B
PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 overexpression	Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
PD-L1 overexpression	Triple Negative Breast Cancer	PD-L1 overexpression	Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	M7824 Sensitive: B - Late Trials M7824 Sensitive : B	M7824 Sensitive: B - Late Trials M7824 Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	avelumab Sensitive: B - Late Trials avelumab Sensitive : B	avelumab Sensitive: B - Late Trials avelumab Sensitive : B

PD-L1 overexpression

Associations